Journals / Bakırköy Tıp Dergisi / 2010 / Cilt: 6 - Sayı: 4

Urodynamical and symptomatic comparison of propiverine and trospium treatment for detrusor overactivity

Detrüsör aşırı aktivitesinin tedavisinde propiverin ve trospiyum’un ürodinamik ve semptomatik karşılaştırılması

Pages
158–164
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: This comparative study suggests that both propiverine hydrochlorid and trospium chloride are effective in the treatment of detrusor overactivity but as the expectance from anticholinergic drugs is minimum side effects, so trospium chloride is more advantageous in this view.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study is to compare the effectiveness of trospium chloride and propiverine hydrochlorid on detrusor overactivity in the view of symptoms, urodynamic parameters and quality of life scores.
📊
Key Findings & Data:Materials and Methods: 63 women with urodynamically proven detrusor overactivity included to the prospective randomised controlled study.
💡
Conclusion & Impact:Conclusion: This comparative study suggests that both propiverine hydrochlorid and trospium chloride are effective in the treatment of detrusor overactivity but as the expectance from anticholinergic drugs is minimum side effects, so trospium chloride is more advantageous in this view.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study is to compare the effectiveness of trospium chloride and propiverine hydrochlorid on detrusor overactivity in the view of symptoms, urodynamic parameters and quality of life scores. Materials and Methods: 63 women with urodynamically proven detrusor overactivity included to the prospective randomised controlled study. Group I (n=29) were given propiverine hydrochlorid and Group II (n=34) were given trospium chloride. After 8 week-treatment participants were clinically and urodynamically reevaluated. Outcomes of interest were patient perceived cure or improvement in symptoms, differences in number of incontinent episodes and number of voids in 24 hours, urodynamic measures of bladder function (volume at first sensation, maximum cystometric capacity, and presence of detrusor contractions) and side effects. Results: At the end of the treatment no difference was noted in the aspects of symptomatic and urodynamic improvement but dryness of mouth (34% vs. 11,8%, p=0,031) was statistically significant in propiverine group (p<0,05). Improvement in frequency (40% vs. 43,18%,p>0,05), urgency (55% vs. 63,2%, p>0,05), nocturia (73,03% vs. 77,02%, p>0,05) , urge incontinence (81,73%, vs. 78% p>0,05), episodes and number of ped usage per day (70,97% vs. 60,83%) decreased in group I and group II in a statistically significant manner (p<0,001). According to urodynamic parameters increase in volume at first sensation (46,80% vs. 29,41%, p>0,05), maximum cystometric capacity (21,10% vs.10,5%, p>0,05) and disapperance of detrusor contractions (48,3% vs. 58,8%, p>0,05) were noted in both groups in a statistically significant manner (p<0,001). Improvement of quality of life scores in both groups (p<0,001) and no difference was found between group I and group II scores (p>0,05). Conclusion: This comparative study suggests that both propiverine hydrochlorid and trospium chloride are effective in the treatment of detrusor overactivity but as the expectance from anticholinergic drugs is minimum side effects, so trospium chloride is more advantageous in this view.

Özet

Amaç: Trospiyum klorür ve propiverin hidroklorürün detrüsor aşırı aktivitesi üzerindeki etkinliğinin semptomlar, ürodinamik parametreler ve yaşam kalitesi skorları dikkate alınarak kıyaslanması. Gereç ve Yöntem: Prospektif randomize kontrollü çalışmaya ürodinamik olarak kanıtlanmış detrüsor aşırı aktivitesi (DAA) olan 63 kadın dahil edildi. Grup I’e (n=29) propiverin hidroklorür, Grup II’ye (n=34) trospiyum klorür verildi. Katılımcılar 8 haftalık tedaviden sonra klinik ve ürodinamik olarak tekrar değerlendirildi. Değerlendirmeye alınanlar; hastanın hissettiği iyileşme veya semptomlarda düzelme, inkontinans epizodu, 24 saatlik işeme sayısındaki farklılıklar, mesane fonksyonlarının ürodinamik değerlendirilmesi (ilk his volümü, maksimum sistometrik kapasite, detruüsor kontraksyonları varlığı) ve yan etkilerdir. Bulgular: Tedavi sonrasında semptomatik ve ürodinamik iyileşme yönünde gruplar arasında fark yoktu fakat propiverin grubunda ağız kuruluğu (%34 vs. %11,8, p=0,031) istatistiksel olarak anlamlı (p 0,05), sıkışma hissinde (%55 vs. %63,2, p>0,05), noktüride (%73,03 vs. %77,02, p>0,05), urge inkontinansta (%81,73, vs. %78 p>0,05), kaçırma epizodları ve günlük kullanılan ped sayısında (%70,97 vs. %60,83) düzelme izlendi. Ürodinamik parametrelerdeki düzelme; ilk his volümünde artış (%46,80 vs. %29,41, p>0,05), maksimum sistometrik kapasitede artış (%21,10 vs. %10,5, p>0,05) ve detrüsor kontraksyonlarının kaybolması (%48,3 vs. %58,8, p>0,05) her iki grupta da istatistiksel olarak anlamlı düzeydeydi (p 0,05). Sonuç: Bu karşılaştırmalı çalışmada trospiyum klorür ve propiverin hidroklorürün her ikisininde detrüsor aşırı aktivitesinin tedavisinde etkin olduğu görülmüştür. Fakat antikolinerjik ilaçlarda yan etkinin en az olması hedeflendiği için trospiyum klorür daha avantajlıdır.

🔖

Cite This Article

ÖZGÜR, Ö., ERTÜRK, D., EKİN, M., YAŞAR, L., SAVAN, K. (2010). Urodynamical and symptomatic comparison of propiverine and trospium treatment for detrusor overactivity. Bakırköy Tıp Dergisi, Cilt: 6 - Sayı: 4, 158–164. https://ajindex.com/articles/130517

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Abrams P, Cardozo L, Fall M, et al The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-178
  2. Hunskaar S, Arnold EP, Burgio K, Diokno AC, Herzog AR, Mallett VT. Epidemiology and natural history of urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2000; 11: 301-319
  3. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population based prevalence study. BJU Int 2001; 87: 760-766
  4. Ozerdoğan N, Beji NK, Yalçın O. Urinary incontinence: its prevalence, risk factors and effects on the quality of life of women living in a region of Turkey. Gynecol and Obstet Invest 2004; 58: 145-150
  5. Fitzgerald MP, Thom DH, Wassel-Fyr C, et al. Childhood urinary symptoms predict adult overactive bladder symptoms. J Urol 2006; 175: 989-993
  6. Sampselle CM, Wyman JF, Thomas KK, et al. Continence for women: evaluation of AWHONN’s third research utilization project. Association of Women’s Health Obstetric and Neonatal Nurses. J Obstet Gynecol Neonatal Nurs 2000; 29: 9-17
  7. Hay-Smith EJ, Bo K, Berghmans LC, Hendriks HJ, de Bie RA, van Waalwijk van Doorn ES. Pelvic floor muscle training for urinary incontinence in women. Cochrane Database Syst Rev 2007; 18: CD001407
  8. Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology 2006; 67: 275-280
  9. Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004; 171: 2311-2315
  10. Madersbacher H, Mürtz G, Alloussi S, et al. Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study. BJU Int 2009; 103: 776-781
  11. Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003; 20: 392-399
  12. Junemann KP, Al-Shukri S. Tolerability of trospium chloride and tolterodine in 234 patients with urge syndrome: a double-blind, plasebo-controlled multicentre clinical trial. Neurourol Urodyn. 2000;19:488-490
  13. Alloussi S, Laval KU, Eckert R, et al. Trospium chloride in patient